Cisen Pharmaceutical Co., Ltd. (SHA:603367)

China flag China · Delayed Price · Currency is CNY
13.21
-0.01 (-0.08%)
Jun 9, 2026, 3:00 PM CST
Market Cap5.98B -1.6%
Revenue (ttm)3.37B -10.1%
Net Income408.45M -16.6%
EPS0.90 -16.6%
Shares Out 452.75M
PE Ratio14.67
Forward PEn/a
Dividend0.32 (2.42%)
Ex-Dividend DateJun 3, 2026
Volume4,346,910
Open13.22
Previous Close13.22
Day's Range13.11 - 13.45
52-Week Range13.10 - 35.20
Beta0.14
Analystsn/a
Price Targetn/a
Earnings DateAug 25, 2026

About Cisen Pharmaceutical

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal dru... [Read more]

Sector Healthcare
Founded 1970
Employees 3,114
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603367
Full Company Profile

Financial Performance

In 2025, Cisen Pharmaceutical's revenue was 3.44 billion, a decrease of -13.48% compared to the previous year's 3.98 billion. Earnings were 421.25 million, a decrease of -17.22%.

Financial Statements